EGFR and non-small cell lung carcinoma: Amivantamab + lazertinib significantly outperformed both lazertinib (HR, 0.60, 95% CI, 0.36–0.99) and osimertinib (HR, 0.66, 95% CI, 0.51–0.89) with respect to its ability to prolong NSCLC cases’ PFS with EGFR 19del mutations.